KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Income from Non-Controlling Interests (2016 - 2025)

Historic Income from Non-Controlling Interests for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q3 2025 value amounting to $1.0 million.

  • Teva Pharmaceutical Industries' Income from Non-Controlling Interests fell 9787.23% to $1.0 million in Q3 2025 from the same period last year, while for Dec 2025 it was $7.0 million, marking a year-over-year increase of 10218.75%. This contributed to the annual value of $7.0 million for FY2025, which is 10218.75% up from last year.
  • Teva Pharmaceutical Industries' Income from Non-Controlling Interests amounted to $1.0 million in Q3 2025, which was down 9787.23% from $6.0 million recorded in Q1 2025.
  • Teva Pharmaceutical Industries' Income from Non-Controlling Interests' 5-year high stood at $47.0 million during Q3 2024, with a 5-year trough of -$280.0 million in Q1 2024.
  • Moreover, its 5-year median value for Income from Non-Controlling Interests was $3.0 million (2022), whereas its average is -$21.3 million.
  • Within the past 5 years, the most significant YoY rise in Teva Pharmaceutical Industries' Income from Non-Controlling Interests was 48750.0% (2024), while the steepest drop was 155000.0% (2024).
  • Teva Pharmaceutical Industries' Income from Non-Controlling Interests (Quarter) stood at $7.0 million in 2021, then tumbled by 557.14% to -$32.0 million in 2022, then skyrocketed by 112.5% to $4.0 million in 2023, then tumbled by 1550.0% to -$58.0 million in 2024, then soared by 101.72% to $1.0 million in 2025.
  • Its Income from Non-Controlling Interests was $1.0 million in Q3 2025, compared to $6.0 million in Q1 2025 and -$58.0 million in Q4 2024.